August 1987

A Clinical Trial of a Monocomponent Pertussis Toxoid Vaccine

Author Affiliations

From the Department of Pediatrics, University of Linköping, Linköping, Sweden (Dr Hedenskog); the National Bacteriological Laboratory, Stockholm (Drs Granström and Tiru); the Department of Pediatrics, Karolinska Institute, Sachs' Childrens Hospital, Stockholm (Dr Olin); and the Japanese National Institute of Health, Tokyo (Dr Sato).

Am J Dis Child. 1987;141(8):844-847. doi:10.1001/archpedi.1987.04460080030021

• We compared a monocomponent pertussis toxoid vaccine preparation (JNIH-7) in a double-blind, randomized study with another component vaccine (JNIH-6) containing pertussis toxoid and filamentous hemagglutinin in equal proportions. Monocomponent pertussis toxoid vaccines have not been tested previously in children. This trial comprised 255 previously nonimmunized children 6 to 10 months old who were given two 0.5-mL subcutaneous injections of either vaccine four to five weeks apart. Prevaccination and postvaccination serum samples from 235 infants showed an antitoxin seroconversion rate of 100% in both groups. Adverse reactions were few and mild, with local reactions occurring more often after administration of the second dose and among recipients of the two-component vaccine (P<.05).

(AJDC 1987;141:844-847)